Real-world evidence shows that switching between biosimilars does not raise safety or efficacy concerns, a National Health Service briefing document on adalimumab has advised prescribers. By using the best-value adalimumab product available, NHS England expects to save more than £300m ($370m) in its current financial year, equivalent to about three-quarters of its historical spending on reference brand Humira.
An updated briefing by NHS England’s Regional Medicines Optimisation Committee recognizes the theoretical concerns around immunogenicity with biosimilar-to-biosimilar switching. It...






